NCT06971744 2025-12-22
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Phase 2 Recruiting
Clinical Trials
12 trialsNCT03077451 2025-12-17
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT01959672 2023-10-10
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT02207439 2023-07-25
Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00003008 2023-06-15
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03050060 2022-06-22
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
Phase 2 Terminated
NCT01108666 2021-07-07
Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT01925378 2020-11-12
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT01065844 2019-10-09
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
University of Iowa
Phase 2 Completed
NCT02188537 2019-06-26
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Swiss Cancer Institute
Phase 2 Completed
NCT00791336 2017-07-28
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
University of Iowa
Phase 2 Terminated
NCT00002185 2005-06-24
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
NIH AIDS Clinical Trials Information Service
Phase 2 Completed